The Effect of Uric Acid Decrement on Endothelial Function in Patients With Chronic Renal Failure

Istanbul University

Status: Completed

Conditions: Chronic Kidney Disease; Hyperuricemia

Treatments: Drug: allopurinol

Study type: Interventional

Funder types: Other

Identifiers

NCT00978653

200931386

Details and patient eligibility

About

In this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on endothelial dysfunction in patients with chronic kidney disease.

Full description

Endothelial dysfunction (ED) is a key event in the development of atherosclerotic cardiovascular disease observed in patients with chronic kidney disease (CKD). Experimental models have shown that hyperuricemia causes hypertension and renin angiotensin system activation. In this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on ED in patients with CKD.

Enrollment: 20 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Laboratory finding of hyperuricemia
• Patients between ages of 18 and 60 years
• Non-diabetic patients
• Creatinine clearance values between 20 and 60 mL/min/1.73 m2

Exclusion criteria

• Low (< 20 ml/min/1.73 m2) creatinine clearance,
• Patients with diabetes mellitus, ischemic heart disease, acute coronary syndrome, congestive heart failure (CHF) (New York Heart Association class II or greater), valvular heart disease and a history of cerebral infarction or transient ischemic attack.
• Patients taking urate lowering medication (allopurinol and probenecid)

Trial design

Primary purpose: Screening

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Allopurinol

Experimental group

Description:

Hyperuricemic (uric acid (UA)\>7 mg/dL), nondiabetic CKD patients without any comorbidity, age\<60 years with creatinine clearance (CrCl) between 20 and 60ml/min were evaluated.

Treatment:

Drug: allopurinol